samedan logo

 
 
spacer
home > ict > summer 2021 > anti-infective development requires a new approach to clinical trial design
PUBLICATIONS
International Clinical Trials

Anti-Infective Development Requires a New Approach to Clinical Trial Design


The fight against COVID-19 isnít over yet. In the US, hospitalisations due to the virus continue, albeit at the lowest rate since the start of the pandemic. States with low vaccination rates run the added risk of SARS-CoV-2 Delta variant outbreaks, and the potential for other variants to emerge cannot be discounted. The ongoing struggle to control the virus highlights the need for rapidly deployed antiviral drugs and vaccines. We need them to better combat this virus, as well as diseases such as malaria, tuberculosis, and pneumonia. The speed at which the industry develops these treatments will have a direct impact on global health, and the magnitude with which we experience future pandemics. Government funding, years of previous coronavirus research, prompt action from regulators, and advanced technology all played a role in giving the world a COVID-19 vaccine in less than a year. While itís unlikely all these forces will come together in the same way again, we can learn from the events that led to the COVID-19 vaccines, as well as other studies deployed during the pandemic. These lessons help us to find practical solutions that allow us to develop vaccines and anti-infectives more efficiently and at a lower cost.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the Author

Chief Business Officer, Jonathan Andrus, leads Clinical Inkís solution management teams to help sponsors and CROs better leverage eSource DDC, eCOA, ePRO, and eConsent data. He forges strategic partnerships with sponsors, CROs, regulatory bodies, and clinical research professionals and is responsible for P&L across Clinical Inkís products and services. Jonathan was previously at BioClinica where he led eClinical Solutions.

jonathan.andrus@clinicalink.com
Print this page
Send to a friend
Privacy statement
News and Press Releases

Bayer Strengthens Drug Discovery Platform Through Acquisition of Vividion Therapeutics

Berlin, Germany, August 5, 2021 Ė Bayer AG today announced the acquisition of Vividion Therapeutics, Inc. (Vividion), a US-headquartered biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics.
More info >>

White Papers

Recommendations Sourcing Human Biospecimens

BioIVT

The foundations for protecting human research subjects come from the ethical principles surrounding the Belmont report : Respect for persons, beneficence, and justice. The use of human biospecimens in research supports these principles with legal and ethical regulations - the most important of which is permission.(1) This permission may come directly from the donor or granted by others with authorization to protect the interests of biospecimen donors.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement